SAN DIEGO, Oct. 28, 2013 /PRNewswire/ -- New two-year results of a Phase 3 study sponsored by Janssen Research & Development, LLC (Janssen) showed that SIMPONI ® ARIA™ (golimumab) for infusion in ...

First Anti-TNF Infusion Therapy Approved in More Than a Decade for Patients Living with Moderately to Severely Active Rheumatoid Arthritis "Phase 3 data showed treatment with SIMPONI ARIA plus ...

HORSHAM, Pa., Sept. 2, 2015 /PRNewswire/ -- Janssen Biotech, Inc. announced today the approval of a U.S. Food and Drug Administration (FDA) Supplemental Biologics License Application (sBLA) for ...

Please provide your email address to receive an email when new articles are posted on . Janssen announced it has received FDA approvals for Simponi Aria for the treatment of adults with psoriatic ...

Johnson & Johnson (J&J) can now offer rheumatoid arthritis (RA) patients in the US an alternative to its subcutaneous version of Simponi after regulators approved the intravenous version Simponi Aria.

SIMPONI ARIA (golimumab) 50mg/4mL single-use vial Simponi Aria (golimumab for infusion; Janssen Biotech) has received approval from the FDA for the treatment of adults with moderately to severely ...

The US Food and Drug Administration (FDA) has approved golimumab (Simponi Aria, Janssen Biotech, Inc), intravenous (IV) formulation in combination with methotrexate, for the treatment of moderately to ...

What Is Simponi, and Why Does It Matter? The FDA has approved Simponi (golimumab) for children with moderately to severely active ulcerative colitis (UC) who weigh at least 15 kilograms (33 pounds).

SIMPONI(TM) (golimumab) Receives FDA Approval as First Once-Monthly Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis First Subcutaneous Anti-TNF to Launch ...